Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

electroCore, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ROCKAWAY, N.J., DEC. 02, 2025 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR) (ELECTROCORE OR THE COMPANY), A BIOELECTRONIC TECHNOLOGY COMPANY, TODAY ANNOUNCED THE PUBLICATION OF A PEER REVIEWED PAPER TITLED NON-INVASIVE TRANSCUTANEOUS VAGAL NERVE STIMULATION ENHANCES MOOD, TASK PERFORMANCE, AND LEARNING IN A HIGH-STRESS MILITARY TRAINING ENVIRONMENT WHICH WILL BE PRESENTED AT THE APPLIED HUMAN FACTORS AND ERGONOMICS (AHFE2025) CONFERENCE ON DECEMBER 8, 2025.

TAC-STIM DEMONSTRATES SIGNIFICANT PERFORMANCE IMPROVEMENTS IN ACTIVE-DUTY UNITED STATES AIR FORCE AIRMEN

ROCKAWAY, N.J., NOV. 10, 2025 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY, ANNOUNCED TODAY THAT MANAGEMENT WILL PARTICIPATE AT THECANACCORD GENUITY MEDTECH, DIAGNOSTICS AND DIGITAL HEALTH & SERVICES FORUM.

ELECTROCORE TO PARTICIPATE AT THE CANACCORD GENUITY MEDTECH, DIAGNOSTICS AND DIGITAL HEALTH & SERVICES FORUM

NET SALES OF $8.7 MILLION INCREASED 33% VS. Q3 2024; YTD NET SALES OF $22.8 MILLION INCREASED 26% VS. FIRST NINE MONTHS OF 2024

ELECTROCORE ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS

ROCKAWAY, N.J., OCT. 23, 2025 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY, ANNOUNCED TODAY THAT IT WILL REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AFTER THE CLOSE OF THE MARKET ON WEDNESDAY, NOVEMBER 5, 2025.

ELECTROCORE TO ANNOUNCE THIRD QUARTER SEPTEMBER 30, 2025 FINANCIAL RESULTS ON WEDNESDAY, NOVEMBER 5, 2025

ROCKAWAY, N.J., OCT. 03, 2025 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (THE COMPANY), (NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY, TODAY ANNOUNCED THAT JENNIFER HAYES WILL BE JOINING ELECTROCORE, EFFECTIVE OCTOBER 6, 2025, AS THE COMPANY'S VICE PRESIDENT, HUMAN RESOURCES AND EMPLOYEE SUCCESS. THE COMPENSATION COMMITTEE OF ELECTROCORE'S BOARD OF DIRECTORS GRANTED 10,000 RESTRICTED STOCK UNITS (RSUS) TO MS. HAYES IN CONNECTION WITH THE COMMENCEMENT OF HER EMPLOYMENT. THE RSUS WERE GRANTED AS AN INDUCEMENT MATERIAL TO MS. HAYES' COMMENCEMENT OF EMPLOYMENT PURSUANT TO NASDAQ LISTING RULE 5635(C)(4). ONE-THIRD OF THE RSUS WILL VEST ON EACH OF THE FIRST, SECOND AND THIRD ANNIVERSARIES OF THE DATE OF GRANT, SUBJECT TO MS. HAYES' CONTINUED EMPLOYMENT BY THE COMPANY ON THE APPLICABLE VESTING DATE. UPON VESTING, THE RSUS SHALL BE SETTLED IN SHARES OF THE COMPANY'S COMMON STOCK.

ELECTROCORE ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

ROCKAWAY, N.J., SEPT. 30, 2025 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY, TODAY ANNOUNCED THE PUBLICATION OF A PEER-REVIEWED STUDY IN FRONTIERS IN NEUROLOGY DEMONSTRATING THE EFFECTIVENESS OF GAMMACORE NON-INVASIVE VAGUS NERVE STIMULATION (NVNS) IN REDUCING PERSISTENT SYMPTOMS ASSOCIATED WITH MILD TRAUMATIC BRAIN INJURY (MTBI).

GAMMACORE NON-INVASIVE VAGUS NERVE STIMULATION (NVNS) AS AN ADJUNCTIVE TREATMENT ASSOCIATED WITH IMPROVEMENTS IN PERSISTENT POST-CONCUSSION SYMPTOMS

ROCKAWAY, N.J., SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY, TODAY ANNOUNCED THAT GAMMACORE SAPPHIRE (NVNS) HAS BEEN INCLUDED IN A LONG-TERM REIMBURSEMENT POLICY LAUNCHED BY THE NATIONAL INSTITUTE FOR HEALTH AND DISABILITY INSURANCE (RIZIV / INAMI) IN BELGIUM.

ELECTROCORE ANNOUNCES REIMBURSEMENT APPROVAL FOR GAMMACORE BY RIZIV/INAMI IN BELGIUM

ROCKAWAY, N.J., SEPT. 22, 2025 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY, TODAY ANNOUNCED THAT ITS TRUVAGA PLUS HANDHELD VAGUS NERVE STIMULATION (NVNS) DEVICE HAS BEEN NAMED THE BEST RELAXATION GADGET IN ESQUIRE'S 2025 SLEEP AWARDS.

ELECTROCORE'S TRUVAGA PLUS NAMED BEST RELAXATION GADGET IN ESQUIRE'S 2025 SLEEP AWARDS

ROCKAWAY, N.J., SEPT. 10, 2025 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (THE COMPANY), (NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY, TODAY ANNOUNCED THAT ANDY BROWN HAS JOINED ELECTROCORE, EFFECTIVE SEPTEMBER 9, 2025, AS THE COMPANY'S VP, CORPORATE CONTROLLER. THE COMPENSATION COMMITTEE OF ELECTROCORE'S BOARD OF DIRECTORS GRANTED 10,000 RESTRICTED STOCK UNITS (RSUS) TO MR. BROWN IN CONNECTION WITH THE COMMENCEMENT OF HIS EMPLOYMENT. THE RSUS WERE GRANTED AS AN INDUCEMENT MATERIAL TO MR. BROWN'S COMMENCEMENT OF EMPLOYMENT PURSUANT TO NASDAQ LISTING RULE 5635(C)(4). 33% OF THE RSUS WILL VEST ON EACH OF THE FIRST, SECOND AND THIRD ANNIVERSARIES OF THE DATE OF GRANT, SUBJECT TO MR. BROWN'S CONTINUED EMPLOYMENT BY THE COMPANY ON THE APPLICABLE VESTING DATE. UPON VESTING, THE RSUS SHALL BE SETTLED IN SHARES OF THE COMPANY'S COMMON STOCK.

ROCKAWAY, N.J., SEPT. 05, 2025 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY, ANNOUNCED TODAY THE DEPARTURE OF PETER CUNEO FROM THE BOARD OF DIRECTORS AND THAT THOMAS J. ERRICO, MD, HAS BEEN ELECTED TO SUCCEED MR. CUNEO AS CHAIRMAN OF THE BOARD, EFFECTIVE SEPTEMBER 2, 2025. MR. CUNEO WILL CONTINUE AS A STRATEGIC ADVISOR TO THE COMPANY.

electroCore, Inc.

ECOR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

electroCore, Inc.

ECOR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ECOR